A new cross-sectional analysis reveals that young adult cancer survivors in the United States face a significantly higher ...

The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...

Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: ...

Matched sibling donors (MSD) and matched unrelated donors (MUD) continue to yield the best 2-year survival outcomes following allogeneic hematopoietic cell transplantation (HCT), while mismatched ...

Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases. During a visit to Columbia University’s Herbert Irving Comprehensive Cancer Center, ...

This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...

Final analysis from the phase 2 OVATION 2 trial (NCT03393884) has demonstrated a continued and growing overall survival (OS) ...

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...